64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.
Funding
$59.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Developing optimized mammalian cell lines for cell and gene therapies is a time-consuming and challenging process. Traditional cell line development methods often struggle to efficiently produce cell lines with the specific characteristics required for next-generation therapeutics.
Solution
64x Bio offers a high-throughput genome engineering platform designed to accelerate the discovery and optimization of mammalian cell lines. This platform combines novel genome engineering techniques with computational tools in a design loop, enabling the generation of highly optimized cell lines that may be unattainable through conventional methods. By enhancing the design and manufacturing process, 64x Bio's technology aims to help pharmaceutical and biotechnology companies more effectively bring cell and gene therapies to patients. The platform is specifically focused on cell lines used in the production of cell and gene therapies.
Target Audience
The primary customers are pharmaceutical and biotechnology companies, as well as Contract Development and Manufacturing Organizations (CDMOs), involved in the development and manufacturing of cell and gene therapies.
Features
- High-throughput genome engineering for rapid cell line modification.
- Computational tools integrated into a design loop for iterative optimization.
- Focus on mammalian cell lines used in cell and gene therapies.
- Platform designed to improve the efficiency of cell line development.